Literature DB >> 22699536

Jaw-opening oromandibular dystonia secondary to Wilson's disease treated with botulinum toxin type A.

Hélio A G Teive1, Leandro E Klüppel, Renato P Munhoz, Nílson Becker, Paulo R Müller, Lineu C Werneck.   

Abstract

We have reported a case series of five patients with jaw-opening oromandibular dystonia secondary to Wilson's disease (WD), in which the patients were treated with botulinum toxin type A (BTX-A). In all cases, dystonia score was partially reduced three weeks after injections. The most common side effect was transient mild dysphagia. This preliminary study showed that jaw-opening oromandibular dystonia in WD may be partially responsive to the use of BTX-A.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22699536     DOI： 10.1590/s0004-282x2012000600005

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN： 0004-282X            Impact factor:   1.420


  8 in total

Review 1.  Clinical management of Wilson disease.

Authors:  Peter Hedera
Journal:  Ann Transl Med       Date:  2019-04

Review 2.  Movement disorders of the mouth: a review of the common phenomenologies.

Authors:  C M Ghadery; L V Kalia; B S Connolly
Journal:  J Neurol       Date:  2022-07-29       Impact factor: 6.682

Review 3.  The Role of Botulinum Toxin A in Treatment of Temporomandibular Joint Disorders: A Review.

Authors:  Rana Ataran; Ayla Bahramian; Zahra Jamali; Vahid Pishahang; Homayoon Sadeghi Barzegani; Parvin Sarbakhsh; Javad Yazdani
Journal:  J Dent (Shiraz)       Date:  2017-09

4.  Brief considerations on the dispensation profile of the botulinum toxin type A by the Brazilian Unified Health System for treatment of dystonias: Datasus data.

Authors:  Hsin Fen Chien; Ana Lucia Zuma de Rosso; André Sobierajski Dos Santos; Carlos Roberto de Mello Rieder; Debora Palma Maia; Delson José da Silva; Marcio da Cunha Andrade; Marcus Vinicius Della Coletta; Maria do Desterro Leiros da Costa; Nasser Allam; Roberto César Pereira do Prado; Vanderci Borges; Vitor Tumas; Wagner de Goes Horta
Journal:  eNeurologicalSci       Date:  2016-07-19

5.  Oromandibular Dystonia: A Clinical Examination of 2,020 Cases.

Authors:  Laura M Scorr; Stewart A Factor; Sahyli Perez Parra; Rachel Kaye; Randal C Paniello; Scott A Norris; Joel S Perlmutter; Tobias Bäumer; Tatiana Usnich; Brian D Berman; Marie Mailly; Emmanuel Roze; Marie Vidailhet; Joseph Jankovic; Mark S LeDoux; Richard Barbano; Florence C F Chang; Victor S C Fung; Sarah Pirio Richardson; Andrew Blitzer; H A Jinnah
Journal:  Front Neurol       Date:  2021-09-16       Impact factor: 4.003

Review 6.  Botulinum Toxin Therapy for Oromandibular Dystonia and Other Movement Disorders in the Stomatognathic System.

Authors:  Kazuya Yoshida
Journal:  Toxins (Basel)       Date:  2022-04-14       Impact factor: 5.075

7.  Dystonia in Patients with Spinocerebellar Ataxia 3 - Machado-Joseph disease: An Underestimated Diagnosis?

Authors:  Ligia Maria Perrucci Catai; Carlos Henrique Ferreira Camargo; Adriana Moro; Gustavo Ribas; Salmo Raskin; Hélio Afonso Ghizoni Teive
Journal:  Open Neurol J       Date:  2018-05-31

8.  Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson's Disease: Six Cases and Literature Review.

Authors:  Harald Hefter; Sara Samadzadeh
Journal:  Toxins (Basel)       Date:  2021-03-29       Impact factor: 4.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.